# EVERTEC

Type: Company (EVTC)

Source: GetYourBrief — https://getyourbrief.com/entity/evertec
Canonical HTML page: https://getyourbrief.com/entity/evertec

## Recent coverage (4 stories, network-wide)

### Figure (FIGR) Q4 Earnings: Blockchain Lending and Stablecoin Adoption Surge
2026-02-27 00:15:43 · Sector: crypto · Sentiment: Positive · Impact: 7/10 · Sources: 19

Figure reported a massive 131% increase in blockchain-based loan volume and a 426% surge in EBITDA, signaling a major shift toward institutional DeFi. Payoneer and Evertec also highlighted the growing role of stablecoins and digital rails in global B2B and Latin American payment markets.
Full story: https://getcryptobrief.com/story/figure-figr-q4-earnings-blockchain-lending-stablecoin-adoption

### Earnings Preview: Frontdoor, Natera, Lantheus, and EVERTEC Set to Report
2026-02-25 05:15:03 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4

A diverse group of mid-cap leaders across home services, healthcare, and fintech are preparing to release their quarterly results. Investors are focused on subscriber retention at Frontdoor and the continued clinical adoption of diagnostics at Natera and Lantheus.
Full story: https://getfinancebrief.com/story/earnings-preview-ftdr-ntra-lnth-evtc-2026

### Natera and Lantheus Earnings: Precision Diagnostics and Radiopharma in Focus
2026-02-25 05:15:00 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Full story: https://getbiobrief.com/story/natera-lantheus-earnings-preview-biotech-diagnostics

### Precision Diagnostics and Radiopharma Lead Healthcare Q4 Earnings Outlook
2026-02-25 05:14:27 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Investors are closely monitoring upcoming earnings from Natera and Lantheus as bellwethers for the precision medicine and radiopharmaceutical sectors. These reports will highlight the scaling of molecular residual disease testing and the competitive dynamics of advanced prostate cancer imaging.
Full story: https://gethealthbrief.com/story/natera-lantheus-earnings-preview-precision-medicine-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.